Roche Unveils Promising Data for Elecsys Amyloid Plasma Panel in Alzheimer’s Diagnosis at CTAD 2024

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced new late-breaking data on its Elecsys Amyloid Plasma Panel (combination of pTau181 and ApoE4), for Alzhei...

November 01, 2024 | Friday | News
Eli Lilly Reports Positive Phase 3b Results for Donanemab, Reducing Amyloid-Related Edema in Alzheimer's Patients

Eli Lilly and Company (NYSE: LLY) announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related imaging...

October 30, 2024 | Wednesday | News
MilliporeSigma Rolls Out €70 Million Expansion to Transform St. Louis into a Hub for Advanced ADC Manufacturing and Biopharma Innovation

Merck, a leading science and technology company, announced a € 70 million expansion of its ADC manufacturing capabilities and capacity at its Bioconju...

October 30, 2024 | Wednesday | News
RemeGen's Taicercept® for Generalized Myasthenia Gravis Receives Priority Review from China’s Drug Administration

RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced that the marketing applica...

October 29, 2024 | Tuesday | News
AstraZeneca’s Fasenra Receives EU Approval as Add-On Treatment for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing ...

October 29, 2024 | Tuesday | News
Orexo Begins Dosing for Intranasal Epinephrine Study in Allergy Patients, Aiming to Advance OX640 Toward Regulatory Approval

OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epine...

October 28, 2024 | Monday | News
Novartis Unveils Promising 12-Month Data for Fabhalta® in C3 Glomerulopathy at ASN Kidney Week 2024

Novartis presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3...

October 28, 2024 | Monday | News
Regeneron and Sanofi Present Positive Phase 3 Results for Dupixent in Chronic Spontaneous Urticaria

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi will present positive data from the Phase 3 LIBERTY-CUPID Study C evaluating the inves...

October 25, 2024 | Friday | News
GSK Announces Promising Data for Arexvy Vaccine in Younger Adults at Risk for RSV

GSK plc (LSE/NYSE: GSK) announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at inc...

October 25, 2024 | Friday | News
Positive Phase 3 Results for Dupixent in Chronic Spontaneous Urticaria to be Unveiled at ACAAI 2024

Positive data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent (dupilumab) in biologic-naive patients with uncontrolle...

October 25, 2024 | Friday | News
European Commission Approves KEYTRUDA for New Indications in Gynecologic Cancers

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved two new indications for K...

October 25, 2024 | Friday | News
Eli Lilly’s Donanemab Receives MHRA Approval for Alzheimer's Treatment in Great Britain

Eli Lilly and Company (NYSE: LLY) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization fo...

October 24, 2024 | Thursday | News
Pfizer Expands Pneumococcal Vaccine Recommendations for Adults 50 and Older Following CDC Advisory Committee Vote

Pfizer Inc. (NYSE: PFE) announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practice (ACIP)...

October 24, 2024 | Thursday | News
Sangamo Therapeutics Secures FDA Pathway for Accelerated Approval of Gene Therapy for Fabry Disease

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced the outcome of a recent successful interaction with the U.S.&nbs...

October 23, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close